P-CABs Do Not Increase Risk for C difficile Infection
A recent study found that potassium-competitive acid blockers (P-CABs) do not increase the risk of Clostridioides difficile infection compared to proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs). The research analyzed data from over 200,000 patients prescribed these medications between 2019 and 2024. Findings suggest that P-CABs may even be associated with a reduced risk of infection under certain conditions.
- ▪Individuals using P-CABs had an incidence rate of 0.18% for C difficile infection compared to 0.27% for PPI users.
- ▪No statistically significant difference in the risk for C difficile infection was observed between P-CABs and H2RAs.
- ▪The study was led by Gyeongmin Lim from Sungkyunkwan University in South Korea.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Individuals who used potassium-competitive acid blockers (P-CABs) did not face a higher risk for Clostridioides difficile infection than those who used proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H2RAs).METHODOLOGY:Previous observational studies have linked PPI to a higher risk for C difficile infection; P-CABs are a relatively newer class of acid-suppressive agents, but real-world evidence on the risk for C difficile infection with P-CABs remains limited.Researchers conducted a retrospective cohort study to determine whether initiating P-CABs increases the risk for C difficile infection compared with initiating PPI or H2RAs in adults who were newly prescribed these acid-suppressive drugs between 2019 and 2024.P-CABs included tegoprazan and fexuprazan; PPIs…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
